BACKGROUND: The efficacy of infliximab in @entity31 ( @entity31 ) and indeterminate @entity1960 has been poorly assessed and preliminary results are conflicting. METHODS: The records of 30 @entity1 treated with infliximab for @entity31 (n=19) or indeterminate @entity1960 (n=11) were reviewed. Infliximab was given because of @entity134 resistance (n=18), @entity734 (n=5) or intolerance (n=7); five @entity1 had failed on cyclosporin; 19 @entity1 had a severe flare-up. RESULTS: Median duration of follow-up was 10 months. In 28 @entity1 with active disease, the response rate was 75% at day 7, with 43% having a complete remission, and 50% at month 1, with 32% having a complete remission. Among the 22 responders, the probability of relapse was 73% at month 6. The probability of complete remission without @entity230 , taking into account the re-treatment for relapse (n=11), was 57% (95% confidence interval (CI): 45% to 69%) at month 6. The probability of colectomy was 33% (95% CI: 23% to 43%) at month 12. In indeterminate @entity1960 , response rate was only 50% at day 7 and 30% at month 1. Concomitant use of antimetabolite agents was associated with better results. CONCLUSIONS: Infliximab was able to induce a rapid response in some @entity1 with @entity31 or indeterminate @entity1960 refractory to conventional treatment. Long-term results were less favourable, with frequent relapses, and about one-third of the @entity1 required a colectomy.

Infliximab for refractory XXXX or indeterminate @entity1960 : an open-label multicentre study.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity31 :: ('MESH:D003093', 'Disease') :: ['ulcerative colitis', 'UC'] @entity1960 :: ('MESH:D003092', 'Disease') :: ['colitis'] @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid'] @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids'] @entity734 :: ('MESH:D019966', 'Disease') :: ['dependence']
@entity31 :: (MESH:D003093,Disease) :: ['ulcerative colitis']
